CASTLE BIOSCIENCES INC. overview

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced findings from a study that evaluated uveal melanoma (UM) patients’ attitudes toward prognostic testing and specifically with respect to DecisionDx-UM ® . Highlights from the study were shared in a poster presentation at the 20th congress of the International Society of Ocular Oncology (ISOO), recently held in Leiden, The Netherlands. The poster, titled “Uveal...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the clinical value of the Company’s tests for skin cancer in guiding more informed disease management decisions. Data on each of Castle’s skin cancer tests, as outlined below, was shared during the recent Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2022. DecisionDx ® -Melanoma While patients...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new collaboration with OHSU’s War on Melanoma™ . The War on Melanoma is a multi-faceted public health campaign with a focus on early detection and prevention of melanoma through various education, activism and research programs. The collaboration includes support of various aspects of the War on Melanoma program, including the Start Seeing Melanoma™...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a poster presentation on DecisionDx®-Melanoma at the recent 2022 Fall Clinical Dermatology Conference for PAs & NPs. The poster, titled “Attitudes of Patients with Cutaneous Melanoma Towards Prognostic Testing Using Gene Expression Profiling,” shares results from a survey of 120 melanoma patients regarding prognostic testing with DecisionDx-Melanoma. The...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the JMP Securities Life Sciences Conference on Thursday, June 16, 2022, at 10:30 a.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been selected as the winner of the “Best New Technology Solution – Dermatology” award in the sixth annual MedTech Breakthrough Awards program for its innovative DecisionDx®-Melanoma gene expression profile (GEP) test. DecisionDx-Melanoma leverages Castle’s advanced technologies to identify the risk of metastasis, recurrence and sentinel lymph...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that an abstract demonstrating the ability of the Company’s DecisionDx®-Melanoma test to risk-stratify patients with cutaneous melanoma according to their survival likelihood will be available online during the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually and in Chicago, June 3-7, 2022. Details are as follows:...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new study data demonstrating the ability of its TissueCypher® Barrett’s Esophagus test to independently predict malignant progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with non-dysplastic (ND), indefinite or low-grade dysplasia (LGD) Barrett’s esophagus (BE). The TissueCypher Barrett’s Esophagus test is designed...